tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Kairos Pharma Ltd

KAPA
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
0.454USD
-0.027-5.61%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
1.54M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
์žฅ์™ธ ๊ฑฐ๋ž˜ย 18:30ย (ET)0.454USD-0.006-1.30%

Kairos Pharma Ltd ์ •๋ณด ํšŒ์‚ฌ

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.

Kairos Pharma Ltd ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ KAPA
ํšŒ์‚ฌ ์ด๋ฆ„Kairos Pharma Ltd
์ƒ์žฅ์ผSep 16, 2024
CEOYu (John S)
์ง์› ์ˆ˜1
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒSep 16
์ฃผ์†Œ2355 Westwood Blvd. #139
๋„์‹œLOS ANGELES
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX โ€“ NASDAQ Basic Amex
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ90064
์ „ํ™”18184045541
์›น์‚ฌ์ดํŠธhttps://kairospharma.com
์ข…๋ชฉ ์ฝ”๋“œ KAPA
์ƒ์žฅ์ผSep 16, 2024
CEOYu (John S)

Kairos Pharma Ltd์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
763.88K
-3.47%
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
763.88K
-3.47%
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
763.88K
-3.47%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
796.00
-783.04%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
796.00
-421.98%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
796.00
-421.98%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
796.00
-783.04%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
796.00
-421.98%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
796.00
-783.04%
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
763.88K
-3.47%
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
763.88K
-3.47%
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
763.88K
-3.47%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
796.00
-783.04%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
796.00
-421.98%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
796.00
-421.98%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Kairos Pharma Ltd์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Kairos Pharma Ltd์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Dr. John S. Yu, M.D.

Kairos Pharma Ltd(KAPA)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Kairos Pharma Ltd์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 24๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 1.15M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 5.38%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -1122351.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ